A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates

Gideon Meyerowitz-Katz, Lea Merone, Gideon Meyerowitz-Katz, Lea Merone

Abstract

An important unknown during the coronavirus disease-2019 (COVID-19) pandemic has been the infection fatality rate (IFR). This differs from the case fatality rate (CFR) as an estimate of the number of deaths and as a proportion of the total number of cases, including those who are mild and asymptomatic. While the CFR is extremely valuable for experts, IFR is increasingly being called for by policy makers and the lay public as an estimate of the overall mortality from COVID-19.

Methods: Pubmed, Medline, SSRN, and Medrxiv were searched using a set of terms and Boolean operators on 25/04/2020 and re-searched on 14/05/2020, 21/05/2020 and 16/06/2020. Articles were screened for inclusion by both authors. Meta-analysis was performed in Stata 15.1 by using the metan command, based on IFR and confidence intervals extracted from each study. Google/Google Scholar was used to assess the grey literature relating to government reports.

Results: After exclusions, there were 24 estimates of IFR included in the final meta-analysis, from a wide range of countries, published between February and June 2020. The meta-analysis demonstrated a point estimate of IFR of 0.68% (0.53%-0.82%) with high heterogeneity (p < 0.001).

Conclusion: Based on a systematic review and meta-analysis of published evidence on COVID-19 until July 2020, the IFR of the disease across populations is 0.68% (0.53%-0.82%). However, due to very high heterogeneity in the meta-analysis, it is difficult to know if this represents a completely unbiased point estimate. It is likely that, due to age and perhaps underlying comorbidities in the population, different places will experience different IFRs due to the disease. Given issues with mortality recording, it is also likely that this represents an underestimate of the true IFR figure. More research looking at age-stratified IFR is urgently needed to inform policymaking on this front.

Keywords: COVID-19; Death rate; Global health; Infection-fatality rate; SARS-CoV-2.

Copyright © 2020. Published by Elsevier Ltd.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7524446/bin/fx1_lrg.jpg

References

    1. Aguas R., Corder R.M., King J.G., Goncalves G., Ferreira M.U., Gomes M.G.M. Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics. medRxiv. 2020 2020.07.23.20160762.
    1. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med; 0(0):null.
    1. Anon . Instituto de Salud Carlos III; 2020. ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA.
    1. Anon . Czech Republic Ministry of Health; 2020. Collective immunity study SARS-COV-2-CZ-Preval: preliminary results.
    1. Anon . Finnish Government; Finland: 2020. Weekly Report of the Population Serology Survey of the Corona Epidemic.
    1. Bai Y., Yao L., Wei T., Tian F., Jin D.-Y., Chen L. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407.
    1. Bassett B.A. Strict lower bound on the COVID-19 fatality rate in overwhelmed healthcare systems. medRxiv. 2020 2020.04.22.20076026.
    1. Basu A. Estimating the infection fatality rate among symptomatic COVID-19 cases in the United States. Health Aff (Project Hope) 2020 101377hlthaff202000455.
    1. Bendavid E., Mulaney B., Sood N., Shah S., Ling E., Bromley-Dulfano R. COVID-19 antibody seroprevalence in Santa Clara County, California. medRxiv. 2020 2020.04.14.20062463.
    1. Bryan A., Pepper G., Wener M.H., Fink S.L., Morishima C., Chaudhary A. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020 JCM.00941-20.
    1. Doi A., Iwata K., Kuroda H., Hasuike T., Nasu S., Kanda A. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv. 2020 2020.04.26.20079822.
    1. Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
    1. Ed Slot B.M.H., Reusken Chantal B.E.M. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Epidemiology. 2020 28 April 2020, PREPRINT (Version 1) available at Research Square [+]. In Review.
    1. Erikstrup C., Hother C.E., Pedersen O.B.V., Mølbak K., Skov R.L., Holm D.K. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. medRxiv. 2020 2020.04.24.20075291.
    1. Fernández-Barat L., López-Aladid R., Torres A. The value of serology testing to manage SARS-CoV-2 infections. Eur Respir J. 2020:2002411.
    1. Folkhälsomyndigheten . Public Health Agency of Sweden; Sweden: 2020. The infection fatality rate of COVID-19 in Stockholm — technical report.
    1. Folkhälsomyndigheten, editor. Första resultaten från pågående undersökning av antikroppar för covid-19-virus. Folkhälsomyndigheten; Sweden: 2020.
    1. Fontanet A., Tondeur L., Madec Y., Grant R., Besombes C., Jolly N. Cluster of COVID-19 in northern France: a retrospective closed cohort study. medRxiv. 2020 2020.04.18.20071134.
    1. Garcia-Basteiro A.L., Moncunill G., Tortajada M., Vidal M., Guinovart C., Jimenez A. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. medRxiv. 2020 2020.04.27.20082289.
    1. Ghaffari A., Meurant R., Ardakani A. COVID-19 serological tests: how well do they actually perform? Diagnostics. 2020;10(7):453.
    1. Giorgi Rossi P., Emilia-Romagna COVID-19 working group, Broccoli S., Angelini P. Case fatality rate in patients with COVID-19 infection and its relationship with length of follow up. J Clin Virol. 2020;128:104415.
    1. Grewelle R., De Leo G. Estimating the global infection fatality rate of COVID-19. medRxiv. 2020 2020.05.11.20098780.
    1. Gudbjartsson D.F., Helgason A., Jonsson H., Magnusson O.T., Melsted P., Norddahl G.L. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020
    1. Hallal P., Hartwig F., Horta B., Victora G.D., Silveira M., Struchiner C. Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states. medRxiv. 2020 2020.05.30.20117531.
    1. Herzog S., De Bie J., Abrams S., Wouters I., Ekinci E., Patteet L. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a serial prospective cross-sectional nationwide study of residual samples. medRxiv. 2020 2020.06.08.20125179.2.
    1. Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–939.
    1. Institut SS, editor. Notat: Foreløbige resultater fra den repræsentative seroprævalensundersøgelse af COVID-19. Statens Serum Institut; Denmark: 2020.
    1. Ioannidis J. The infection fatality rate of COVID-19 inferred from seroprevalence data. medRxiv. 2020 2020.05.13.20101253.
    1. IU . Indiana University; Indiana: 2020. ISDH release preliminary findings about impact of COVID-19 in Indiana.
    1. Jason Oke C.H. Centre for Evidence-Based Medicine: University of Oxford; 2020. Global Covid-19 case fatality rates.
    1. Jerkovic I., Ljubic T., Basic Z., Kruzic I., Kunac N., Bezic J. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia. medRxiv. 2020 2020.05.11.20095158.
    1. Jung S.M., Akhmetzhanov A.R., Hayashi K., Linton N.M., Yang Y., Yuan B. Real-time estimation of the risk of death from novel coronavirus (COVID-19) infection: inference using exported cases. J Clin Med. 2020;9(2)
    1. Kahathuduwa C.N., Dhanasekara C.S., Chin S.-H. Case fatality rate in COVID-19: a systematic review and meta-analysis. medRxiv. 2020 2020.04.01.20050476.
    1. Levin A.T., Meyerowitz-Katz G., Owusu-Boaitey N., Cochran K.B., Walsh S.P. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. medRxiv. 2020 2020.07.23.20160895.
    1. Lisboa Bastos M., Tavaziva G., Abidi S.K., Campbell J.R., Haraoui L.-P., Johnston J.C. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516.
    1. Liu K., Chen Y., Lin R., Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020 S0163-4453(20)30116-X.
    1. Mahase E. Covid-19: UK starts social distancing after new model points to 260 000 potential deaths. BMJ. 2020;368(1089)
    1. Modi C., Boehm V., Ferraro S., Stein G., Seljak U. Total COVID-19 mortality in italy: excess mortality and age dependence through time-series analysis. medRxiv. 2020 2020.04.15.20067074.
    1. Modi C., Boehm V., Ferraro S., Stein G., Seljak U. How deadly is COVID-19? A rigorous analysis of excess mortality and age-dependent fatality rates in Italy. medRxiv. 2020 2020.04.15.20067074.
    1. Modig K., Ebeling M. Excess mortality from COVID-19. Weekly excess death rates by age and sex for Sweden. medRxiv. 2020 2020.05.10.20096909.
    1. Nishiura H., Kobayashi T., Yang Y., Hayashi K., Miyama T., Kinoshita R. The rate of underascertainment of novel coronavirus (2019-nCoV) infection: estimation using Japanese passengers data on evacuation flights. J Clin Med. 2020;9(2)
    1. Perez-Saez J., Lauer S.A., Kaiser L., Regard S., Delaporte E., Guessous I. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland. medRxiv. 2020 2020.06.10.20127423.
    1. Rinaldi G., Paradisi M. An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreak. medRxiv. 2020 2020.04.18.20070912.
    1. Roques L., Klein E., Papaix J., Sar A., Soubeyrand S. Using early data to estimate the actual infection fatality ratio from COVID-19 in France. medRxiv. 2020 2020.03.22.20040915.
    1. Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
    1. Russell T.W., Hellewell J., Jarvis C.I., van Zandvoort K., Abbott S., Ratnayake R. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. 2020;25(12)
    1. Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J. Estimating the burden of SARS-CoV-2 in France. Science. 2020:eabc3517.
    1. Scally G., Jacobson B., Abbasi K. The UK’s public health response to covid-19. BMJ. 2020;369:m1932.
    1. Shakiba M., Hashemi Nazari S.S., Mehrabian F., Rezvani S.M., Ghasempour Z., Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. medRxiv. 2020 2020.04.26.20079244.
    1. Silveira M., Barros A., Horta B., Pellanda L., Victora G., Dellagostin O. Repeated population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. medRxiv. 2020 2020.05.01.20087205.
    1. Simon P. Robust estimation of infection fatality rates during the early phase of a pandemic. medRxiv. 2020 2020.04.08.20057729.
    1. Slovenia RO, editor. First study carried out on herd immunity of the population in the whole territory of Slovenia. Republic of Slovenia; Slovenia: 2020.
    1. Snoeck C.J., Vaillant M., Abdelrahman T., Satagopam V.P., Turner J.D., Beaumont K. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. medRxiv. 2020 2020.05.11.20092916.
    1. Sood N., Simon P., Ebner P., Eichner D., Reynolds J., Bendavid E. Seroprevalence of SARS-CoV-2—specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020. JAMA. 2020
    1. Spychalski P., Błażyńska-Spychalska A., Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020
    1. Staines H.M., Kirwan D.E., Clark D.J., Adams E.R., Augustin Y., Byrne R.L. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. medRxiv. 2020 2020.06.07.20124636.
    1. Statistics OFN, editor. Coronavirus (COVID-19) Infection Survey pilot: 5 June 2020. Office for National Statistics; England: 2020.
    1. Streeck H., Schulte B., Kuemmerer B., Richter E., Hoeller T., Fuhrmann C. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. medRxiv. 2020 2020.05.04.20090076.3.
    1. Stringhini S., Wisniak A., Piumatti G., Azman A.S., Lauer S.A., Baysson H. Repeated seroprevalence of anti-SARS-CoV -2 IgG antibodies in a population-based sample from Geneva, Switzerland. medRxiv. 2020 2020.05.02.20088898.
    1. Stringhini S., Wisniak A., Piumatti G., Azman A.S., Lauer S.A., Baysson H. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020
    1. Sutton D., Fuchs K., D’Alton M., Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020
    1. Takahashi S., Greenhouse Bryan, Rodríguez-Barraquer Isabel. OSF Preprints; 2020. Are Sars-cov-2 seroprevalence estimates biased?
    1. Takita M., Matsumura T., Yamamoto K., Yamashita E., Hosoda K., Hamaki T. Preliminary results of seroprevalence of SARS-CoV-2 at community clinics in Tokyo. medRxiv. 2020 2020.04.29.20085449.
    1. Thompson W.W., Moore M.R., Weintraub E., Cheng P.-Y., Jin X., Bridges C.B. Estimating influenza-associated deaths in the United States. Am J Public Health. 2009;99(S2):S225–S230.
    1. Thompson C., Grayson N., Paton R., Lourenço J., Penman B., Lee L.N. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors — a pilot study of the value of serology to determine population exposure. medRxiv. 2020 2020.04.13.20060467.
    1. Tian S., Hu N., Lou J., Chen K., Kang X., Xiang Z. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401–406.
    1. Valenti L., Bergna A., Pelusi S., Facciotti F., Lai A., Tarkowski M. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv. 2020 2020.05.11.20098442.
    1. Verity R., Okell L.C., Dorigatti I., Winskill P., Whittaker C., Imai N. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020
    1. Villa M., Myers J.F., Turkheimer F. COVID-19: recovering estimates of the infected fatality rate during an ongoing pandemic through partial data. medRxiv. 2020 2020.04.10.20060764.
    1. Wilson L. SSRN; 2020. SARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) implied by the serology, antibody, testing in New York City.
    1. Winter A.K., Hegde S.T. The important role of serology for COVID-19 control. Lancet Infect Dis. 2020
    1. Wong J.Y., Wu P., Nishiura H., Goldstein E., Lau E.H.Y., Yang L. Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. Am J Epidemiol. 2013;177(8):834–840.
    1. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. J Med Virol; n/a (n/a).

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel